Jul 2026
Abstract A013: Preclinical Development of a Humanized CD44v9-Directed Antibody-Drug Conjugate for Treatment-Refractory Breast Cancer
Preclinical development of a humanized CD44v9-directed ADC for advanced breast cancer after resistance to existing ADCs is supported, with results reproduced the activity observed in earlier chimeric proof-of-concept studies.
N. Ueno, Dileep R. Reddy, McKenna E. Flynn et al.
· Clinical Cancer Research · 0 citations